Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase

A compound of Formula (I):

• or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein:
• one of X1, X2, X3 and X4 must be N and the others must be C;
• R1 and R1′ are each independently, halogen, hydroxy, cyano, C0-4alkyl, C1-4alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, ethenyl, or ethynyl;
• R2 is C0-4alkyl, COOR6, COR6, C1-4alkoxyC1-4alkyl-, hydroxyC1-4alkyl-, cycloalkylC0-4alkyl-, arylC0-4alkyl-, hetarylC0-4alkyl-, wherein any of the aryl or hetaryl rings are optionally substituted with 1-2 independent halogen, cyano, C1-4alkyl, C1-4alkoxy, —N(C0-4alkyl)(C0-4alkyl), —SO2C1-4alkyl, —SO2N(C0-4alkyl)(C0-4alkyl), hydroxy, fluoromethyl, difluoromethyl, or trifluoromethyl substituents;
• Y is C0-2alkyl or —CH(OH)—;
• Z is CH2, —C(O)—, —O—, >N(C0-4alkyl), >N(C3-6cycloalkyl), or absent;
• but when Y is —CH(OH)—, Z or R3 must be bonded to Y through a carbon-carbon bond;
• R3 is hydrogen, —COOC0-4alkyl, C1-4alkoxy, C1-4alkyl, arylC1-4alkylthio-, —C0-4alkylaryl, —C0-4alkylhetaryl, —C0-4alkylcycloalkyl or —C0-4alkylheterocyclyl, wherein any of the rings is optionally substituted with 1-3 independent halogen, cyano, C1-4alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, —C0-4alkylNHC(O)O(C1-4alkyl), —C0-4alkylNR7R8, —C(O)R9, C1-4alkoxyC0-4alkyl-, —COOC0-4alkyl, —C0-4alkylNHC(O)R9, —C0-4alkylC(O)N(R10)2, —C1-4alkoxyC1-4alkoxy, hydroxyC0-4alkyl-, —NHSO2R10, —SO2(C1-4alkyl), —SO2NR11R12, 5- to 6-membered heterocyclyl, phenylC0-2alkoxy, or phenylC0-2alkyl substituents, wherein phenyl is optionally substituted with 1-2 independent halogen, cyano, C1-4alkyl, C1-4alkoxy, —N(C0-4alkyl)(C0-4alkyl), —SO2C1-4alkyl, —SO2N(C0-4alkyl)(C0-4alkyl), hydroxy, fluoromethyl, difluoromethyl or trifluoromethyl substituents, or two bonds on a ring carbon of the heterocyclyl group optionally can form an oxo (═O) substituent;
• or R3 is —NR4(—C0-4alkylR5);
• R4 is C0-3alkyl, —C2-3alkyl-NR7R8, C3-6cycloalkyl optionally substituted by hydroxyC0-4alkyl- further optionally substituted by hydroxy, C1-2alkoxyC2-4alkyl-, or C1-2alkyl-S(O)n—C2-3alkyl-;
• n is 0, 1, or 2;
• R5 is hydrogen, hydroxyC2-3alkyl-, C1-2alkoxyC0-4alkyl-, or aryl, hetaryl, or heterocyclyl;
• wherein a heterocyclic nitrogen-containing R5 ring optionally is mono-substituted on the ring nitrogen with C1-4alkyl, benzyl, benzoyl, C1-4alkyl-C(O), —SO2C1-4alkyl, —SO2N(C0-4alkyl)(C0-4alkyl), or C1-4alkoxycarbonyl aryl(C1-4alkoxy)carbonyl;
• and wherein the R5 rings are optionally mono-substituted on a ring carbon with halogen, cyano, C1-4alkyl-C(O), C1-4alkyl-SO2—, C1-4alkyl, C1-4alkoxy, hydroxy, —N(C0-4alkyl)(C0-4alkyl), hydroxyC0-4alkyl-, or C0-4alkylcarbamoyl-, provided that no quaternised nitrogen is included;
• or two bonds on a ring carbon of the heterocyclyl group optionally can form an oxo (═O) substituent;
• R6 is C1-4alkyl, aryl, or hetaryl;
• R7 and R8 are independently C0-4alkyl, C3-6cycloalkyl, or CO(C1-4alkyl);
• R9 is C1-4alkyl, or C3-6cycloalkyl;
• R10 is C0-4alkyl, or C3-6cycloalkyl;
• R11 and R12 are independently C0-4alkyl or together with the nitrogen to which they are attached may form a 4- to 6-membered heterocycle;
• and
• wherein there are no nitrogen-oxygen, nitrogen-nitrogen or nitrogen-halogen bonds in linking the three components —Y-Z-R3 to each other.